Mrs Michelle Carol Southerly, SLP | |
Rr 1 Box 34 A, Augusta, WV 26704-9706 | |
(304) 496-8284 | |
(304) 496-9761 |
Full Name | Mrs Michelle Carol Southerly |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | Rr 1 Box 34 A, Augusta, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750407425 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 394 (West Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Michelle Carol Southerly, SLP Rr 1 Box 34 A, Augusta, WV 26704-9706 Ph: (304) 496-8284 | Mrs Michelle Carol Southerly, SLP Rr 1 Box 34 A, Augusta, WV 26704-9706 Ph: (304) 496-8284 |
News Archive
A U.S. Food and Drugs Administration (FDA) panel, this Thursday agreed that a new drug Vivitrol helps alcoholics and opioid addicts kick the habit. The panel voted 11 to 2 that there was sufficient evidence from a single clinical trial that Vivitrol is effective when it comes to helping people addicted to painkillers.
Can a diet high in processed fat and sugar and Type 2 diabetes cause degeneration of intervertebral discs in the spine? If so, what is happening, and can it be prevented? As part of an ongoing collaboration between Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai - a partnership that draws upon the expertise of both schools to address significant health problems - researchers hope to answer those questions by investigating the link between diet, obesity-linked Type 2 diabetes, and intervertebral disc degeneration.
Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the revered list 25 years ago, MSK has held either the first or second spot each year.
Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).
› Verified 3 days ago